Gardasil effective in adolescents
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Merck's human papillomavirus vaccine Gardasil shows a higher efficacy rate in adolescents (male and female) aged 10 to 15 than in young women aged 16 to 23, according to a Phase III study presented May 19 at the European Society of Pediatric Infectious Diseases. In the 1,529-patient trial, seroconversion rates in the combined adolescent cohort (506 female, 510 male) were 100% for HPV types 16, 6 and 11, and 99.9% for HPV 18. Results were identical in the 513 16-23-year old women, except for serotype 18, for which Gardasil produced a 99.1% conversion rate. The study comes on the heels of a Phase II trial published in the April issue of Lancet Oncology, in which the quadrivalent vaccine was shown to significantly reduce the combined incidence of persistent HPV 16, 18, 6 or 11 compared to placebo. Merck plans to file a Gardasil BLA in the second half of 2005 (1Pharmaceutical Approvals Monthly May 2005, In Brief)...
You may also be interested in...
GSK Sees Cervarix Cross-Protection, Age Range As Key Points Of Differentiation
GlaxoSmithKline expects to highlight a broad age range and cross-protection against multiple viral strains to differentiate its human papilloma virus vaccine Cervarix from Merck’s competing vaccine Gardasil.
Merck Gardasil Phase II data
Merck's therapeutic human papilloma virus vaccine Gardasil showed significant protection against infection and pre-cancerous lesions in a Phase II trial, the company says April 6. Two and a half years post-vaccination, the combined incidence of persistent infection from HPV six, 11, 16 or 18 and related genital disease was reduced by 90% compared to placebo (p<0.001). The 552-patient study included women between 16 and 23 years of age, with a primary endpoint of efficacy at day one, month two and month six. Results were published in the April 2005 Lancet Oncology. Merck plans to file a Gardasil BLA in the second half of 2005. GlaxoSmithKline has a royalty stake in Gardasil under a cross-licensing deal announced in February (1Pharmaceutical Approvals Monthly February 2005, p. 18). GSK has not announced a filing timeframe for its own HPV vaccine, Cervarix...
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.